Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
LQDA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q3.23
N/A
-0.24
vs -0.14
Q4.23
N/A
-0.42
vs -0.09
Q1.24
N/A
-0.54
vs -0.18
Q2.24
N/A
-0.37
vs -0.36
Q3.24
N/A
-0.37
vs -0.24
Q4.24
N/A
-0.46
vs -0.42
Q1.25
N/A
-0.45
vs -0.54
Q2.25
N/A
-0.49
vs -0.37
Q3.25
N/A
-0.41
vs -0.37
Q4.25
N/A
-0.24
vs -0.46
Sales Growth
YoY
Current
Estimates
Q3.23
+16%
3.7M vs 3.2M
Q4.23
-15%
4.5M vs 5.4M
Q1.24
-34%
3M vs 4.5M
Q2.24
-24%
3.7M vs 4.8M
Q3.24
+21%
4.4M vs 3.7M
Q4.24
-36%
2.9M vs 4.5M
Q1.25
+5%
3.1M vs 3M
Q2.25
+142%
8.8M vs 3.7M
Q3.25
+313%
18.4M vs 4.4M
Q4.25
+1239%
39M vs 2.9M
Return on Equity
QoQ
Q1.23
+4%
0.04
vs 0.02
Q2.23
+6%
0.06
vs 0.04
Q3.23
-33%
-0.33
vs 0.06
Q4.23
-58%
-0.58
vs -0.33
Q1.24
-47%
-0.47
vs -0.58
Q2.24
-45%
-0.45
vs -0.47
Q3.24
-21%
-0.21
vs -0.45
Q4.24
-50%
-0.50
vs -0.21
Q1.25
-77%
-0.77
vs -0.50
Q2.25
NA
NA
vs -0.77
Institutionnal Ownership
QoQ
Q4.22
96
96
vs 105
-9%
Q1.23
97
97
vs 96
1%
Q2.23
110
110
vs 97
13%
Q3.23
114
114
vs 110
4%
Q4.23
135
135
vs 114
18%
Q1.24
157
157
vs 135
16%
Q2.24
154
154
vs 157
-2%
Q3.24
168
168
vs 154
9%
Q4.24
181
181
vs 168
8%
Q1.25
180
180
vs 181
-1%
globenewswire.com
6 hours ago
seekingalpha.com
10 hours ago
seekingalpha.com
12 hours ago
benzinga.com
14 hours ago
benzinga.com
14 hours ago
zacks.com
16 hours ago
Quote Panel
Key Metrics
Forecast
3621%2026-Revenue
230%2026-EPS
-777%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
13.00(-53.10%)
Number of analyst
1
Last analyst upgrade/downgrade
Oppenheimer
downgradePrevious: Perform
2025-05-19
Now: Underperform
Raymond James
upgradePrevious: Outperform
2024-08-19
Now: Strong Buy
Raymond James
initialisePrevious: Not converted
2024-08-16
Now: Outperform
Oppenheimer
initialisePrevious: Not converted
2024-06-24
Now: Perform
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
NASDAQ
Unprofitable
Unprofitable
1.77Â ( 6.82%)
Relative Strenght
92
Volume Buzz
17%
Earning Acce
No
Dist 52w H.
0%Relative Strength
LQDA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|